A Phase II study of AZD4877 (a novel anti-mitotic agent) in advanced bladder cancer
Study identifier:D2782C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial Cancer
Medical condition
Bladder Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD4877
Sex
All
Actual Enrollment
54
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 May 2008
Primary Completion Date: 01 May 2009
Study Completion Date: 01 Dec 2009
Study design
Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD4877 Single agent AZD4877 | Drug: AZD4877 Intravenous (IV)25mg/weekly |
Contacts
Investigators
Principal Investigator
Gary Hudes
Fox Chase Cancer Center
